Ketamine's brain impact under the microscope in depression study

NCT ID NCT05327699

Recruiting now Knowledge-focused Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how a single dose of ketamine changes brain chemistry and decision-making in people with major depression. Researchers will measure brain glutamate levels and stress responses in 140 participants. The goal is to understand why ketamine helps some people with depression, not to test it as a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ketamine
What this could lead to: If successful, this study could reveal how ketamine changes brain chemistry to reduce depression symptoms, pointing toward better treatments.
What could go wrong: This is a very early, small study focused on understanding brain mechanisms, not testing a proven treatment. Results may not lead to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Fractures, Stress major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MAJOR DEPRESSIVE DISORDER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Emory University
RECRUITING

Atlanta, Georgia, 30322, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.